Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Clinical Assessment Study in Children With Achondroplasia: The PROPEL Trial

NCT04035811 is registered in ClinicalTrials.gov with QED Therapeutics, a BridgeBio company as lead sponsor.

NCT NCT04035811
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04035811 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Clinical Assessment Study in Children With Achondroplasia: The PROPEL Trial
Lead sponsor
QED Therapeutics, a BridgeBio company
Phase
Observational
Overall status
Completed
Start date
August 12, 2019
Completion date
August 27, 2025
Enrollment
271 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

achondroplasia